Associated Papers
Role of Genetic Variations in the Hepatic Handling of Drugs.
Marin JJG et al.
International Journal of Molecular Sciences, 2020
Pharmacogenetics Biomarkers Predictive of Drug Pharmacodynamics as an Additional Tool to Therapeutic Drug Monitoring.
Haufroid V et al.
Therapeutic Drug Monitoring, 2019
Inosine Monophosphate Dehydrogenase Pharmacogenetics in Hematopoietic Cell Transplantation Patients.
McCune JS et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation, 2018
Genetic variations in the mycophenolate mofetil target enzyme are associated with acute GVHD risk after related and unrelated hematopoietic cell transplantation.
Cao W et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation, 2012
The influence of pharmacogenetics and cofactors on clinical outcomes in kidney transplantation.
Picard N et al.
Expert Opinion on Drug Metabolism & Toxicology, 2011
Polymorphisms in type I and II inosine monophosphate dehydrogenase genes and association with clinical outcome in patients on mycophenolate mofetil.
Gensburger O et al.
Pharmacogenetics and Genomics, 2010
An inosine 5'-monophosphate dehydrogenase 2 single-nucleotide polymorphism impairs the effect of mycophenolic acid.
Winnicki W et al.
The Pharmacogenomics Journal, 2010
Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis.
Kooloos WM et al.
Pharmacogenomics, 2010
IMPDH2 genetic polymorphism: a promoter single-nucleotide polymorphism disrupts a cyclic adenosine monophosphate responsive element.
Garat A et al.
Genetic Testing and Molecular Biomarkers, 2009
IMPDH1 gene polymorphisms and association with acute rejection in renal transplant patients.
Wang J et al.
Clinical Pharmacology and Therapeutics, 2008
A novel variant L263F in human inosine 5'-monophosphate dehydrogenase 2 is associated with diminished enzyme activity.
Wang J et al.
Pharmacogenetics and Genomics, 2007